
    
      This is a multi-center, randomized, double blind, placebo-controlled phase â…¡c study to
      evaluate the safety and validity of Aolanti Weipang Tablets in patients with postprandial
      discomfort syndrome of Functional Dyspepsia(FD). This study will consecutive about 12 weeks,
      including 2 weeks of screening, 1 week of blank run-in, 1 week of placebo run-in, 4 weeks of
      double blind treatment and 4 weeks of observation after treatment. The subjects will be
      randomly given orally Aolanti Weikang Tablets or placebo tablets at a 1:1 ratio three times a
      day(tid) with 3 tablets one time for the treatment.
    
  